A Marine λ-Oligocarrageenan Inhibits Migratory and Invasive Ability of MDA-MB-231 Human Breast Cancer Cells through Actions on Heparanase Metabolism and MMP-14/MMP-2 Axis.


Journal

Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729

Informations de publication

Date de publication:
28 Sep 2021
Historique:
received: 21 07 2021
revised: 11 09 2021
accepted: 13 09 2021
entrez: 22 10 2021
pubmed: 23 10 2021
medline: 5 2 2022
Statut: epublish

Résumé

Sugar-based molecules such as heparins or natural heparan sulfate polysaccharides have been developed and widely studied for controlling heparanase (HPSE) enzymatic activity, a key player in extracellular matrix remodelling during cancer pathogenesis. However, non-enzymatic functions of HPSE have also been described in tumour mechanisms. Given their versatile properties, we hypothesized that sugar-based inhibitors may interfere with enzymatic but also non-enzymatic HPSE activities. In this work, we assessed the effects of an original marine λ-carrageenan derived oligosaccharide (λ-CO) we previously described, along with those of its native counterpart and heparins, on cell viability, proliferation, migration, and invasion of MDA-MB-231 breast cancer cells but also of sh-MDA-MB-231 cells, in which the expression of HPSE was selectively downregulated. We observed no cytotoxic and no anti-proliferative effects of our compounds but surprisingly λ-CO was the most efficient to reduce cell migration and invasion compared with heparins, and in a HPSE-dependent manner. We provided evidence that λ-CO tightly controlled a HPSE/MMP-14/MMP-2 axis, leading to reduced MMP-2 activity. Altogether, this study highlights λ-CO as a potent HPSE "modulator" capable of reducing not only the enzymatic activity of HPSE but also the functions controlled by the HPSE levels.

Identifiants

pubmed: 34677445
pii: md19100546
doi: 10.3390/md19100546
pmc: PMC8539239
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Carrageenan 9000-07-1
heparanase EC 3.2.1.-
Glucuronidase EC 3.2.1.31
MMP2 protein, human EC 3.4.24.24
Matrix Metalloproteinase 2 EC 3.4.24.24
MMP14 protein, human EC 3.4.24.80
Matrix Metalloproteinase 14 EC 3.4.24.80

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Int J Mol Med. 2013 May;31(5):1234-42
pubmed: 23467544
Clin Cancer Res. 2011 Mar 15;17(6):1382-93
pubmed: 21257720
PLoS One. 2009;4(4):e5181
pubmed: 19360105
iScience. 2019 May 31;15:360-390
pubmed: 31103854
Oncol Rep. 2020 Aug;44(2):711-721
pubmed: 32627022
Anticancer Res. 2019 Oct;39(10):5261-5284
pubmed: 31570422
Int J Breast Cancer. 2014;2014:839094
pubmed: 24800085
Cell Adh Migr. 2020 Dec;14(1):118-128
pubmed: 32538273
Front Biosci (Landmark Ed). 2015 Jun 01;20:1144-63
pubmed: 25961550
Prog Brain Res. 2014;214:313-51
pubmed: 25410364
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Nat Cell Biol. 2000 Oct;2(10):737-44
pubmed: 11025665
Trends Cancer. 2017 Jun;3(6):391-406
pubmed: 28670628
Exp Cell Res. 2008 Aug 1;314(13):2501-14
pubmed: 18602101
Carbohydr Polym. 2016 Jan 1;135:316-23
pubmed: 26453883
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mar Drugs. 2019 Feb 27;17(3):
pubmed: 30818840
FEBS J. 2013 May;280(10):2294-306
pubmed: 23374281
Nat Med. 1999 Jul;5(7):793-802
pubmed: 10395325
FEBS J. 2017 Jan;284(1):42-55
pubmed: 27758044
Oncotarget. 2014 May 15;5(9):2529-41
pubmed: 24796733
BMC Complement Altern Med. 2016 Aug 04;16:270
pubmed: 27487950
Br J Cancer. 2007 Sep 17;97(6):761-8
pubmed: 17726466
Eur J Cancer. 2010 May;46(7):1177-80
pubmed: 20307970
Biomolecules. 2020 Dec 30;11(1):
pubmed: 33396696
Int J Cancer. 1987 Oct 15;40(4):511-8
pubmed: 3666989
Rambam Maimonides Med J. 2011 Jan 31;2(1):e0019
pubmed: 23908791
Mar Drugs. 2017 May 09;15(5):
pubmed: 28486399
Sci Rep. 2015 Jun 22;5:11062
pubmed: 26098663
Cancer Res. 2015 Sep 15;75(18):3946-57
pubmed: 26249176
Int J Mol Sci. 2019 Feb 15;20(4):
pubmed: 30781344
FASEB J. 2019 Feb;33(2):2910-2927
pubmed: 30332299
J Biol Chem. 2008 Jun 27;283(26):18167-76
pubmed: 18450756
Matrix Biol. 2021 Jun;100-101:173-181
pubmed: 33548399
Molecules. 2018 Nov 08;23(11):
pubmed: 30413079
J Cell Biochem. 2009 Feb 1;106(2):200-9
pubmed: 19115257
J Biol Chem. 2008 Nov 21;283(47):32628-36
pubmed: 18812315
World J Gastroenterol. 2009 Nov 21;15(43):5442-8
pubmed: 19916174
J Gastrointest Surg. 2008 Oct;12(10):1674-81; discussion 1681-2
pubmed: 18704599
Compr Rev Food Sci Food Saf. 2016 Mar;15(2):237-250
pubmed: 33371599
Carbohydr Polym. 2018 Oct 15;198:385-400
pubmed: 30093014
Exp Ther Med. 2014 Oct;8(4):1213-1218
pubmed: 25187827
Oncol Rep. 2017 Jan;37(1):179-184
pubmed: 27878294
Adv Exp Med Biol. 2020;1221:493-522
pubmed: 32274724
Sci Rep. 2019 Apr 30;9(1):6654
pubmed: 31040376
J Biol Chem. 2004 Feb 27;279(9):8047-55
pubmed: 14630925
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Invasion Metastasis. 1992;12(2):112-27
pubmed: 1399400
Clin Breast Cancer. 2021 Oct;21(5):383-390
pubmed: 33781662
Carbohydr Polym. 2017 Jun 15;166:156-165
pubmed: 28385219
J Biol Chem. 2004 Oct 15;279(42):44084-92
pubmed: 15292202

Auteurs

Rémi Cousin (R)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Hugo Groult (H)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Chanez Manseur (C)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Romain Ferru-Clément (R)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Mario Gani (M)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Rachel Havret (R)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Claire Toucheteau (C)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Grégoire Prunier (G)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Béatrice Colin (B)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Franck Morel (F)

Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, Poitiers University, LITEC EA 4331, 86073 Poitiers, France.

Jean-Marie Piot (JM)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Isabelle Lanneluc (I)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Kévin Baranger (K)

Aix-Marseille University, CNRS, INP, Inst Neurophysiopathol, 13385 Marseille, France.

Thierry Maugard (T)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Ingrid Fruitier-Arnaudin (I)

BCBS Group (Biotechnologies et Chimie des Bioressources pour la Santé), Laboratoire Littoral Environnement et Sociétés, La Rochelle University, UMR CNRS 7266, 17000 La Rochelle, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH